APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chronic Rhinosinusitis With Nasal Polyps

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Chronic Rhinosinusitis With Nasal Polyps Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025194 pages

Choose your research edition.

Industry ResearchChronic Rhinosinusitis With Nasal Polyps Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Rhinosinusitis With Nasal Polyps Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Chronic Rhinosinusitis With Nasal Polyps Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Rhinosinusitis With Nasal Polyps Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Rhinosinusitis With Nasal Polyps Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Chronic Rhinosinusitis With Nasal Polyps market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Chronic Rhinosinusitis With Nasal Polyps is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chronic Rhinosinusitis With Nasal Polyps is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chronic Rhinosinusitis With Nasal Polyps is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Chronic Rhinosinusitis With Nasal Polyps is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Chronic Rhinosinusitis With Nasal Polyps include Teva, Sanofi, Novartis, GSK, Wockhardt, West-Ward Pharmaceuticals, Regeneron, Optinose and Genentech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chronic Rhinosinusitis With Nasal Polyps market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chronic Rhinosinusitis With Nasal Polyps and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chronic Rhinosinusitis With Nasal Polyps sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chronic Rhinosinusitis With Nasal Polyps market size, projected growth trends, production technologies, key applications, and end-use industries.

Chronic Rhinosinusitis With Nasal Polyps Segment by Company

Teva

Sanofi

Novartis

GSK

Wockhardt

West-Ward Pharmaceuticals

Regeneron

Optinose

Genentech

AstraZeneca

Apotex Corp.

Akorn

Chronic Rhinosinusitis With Nasal Polyps Segment by Type

Anti-leukotriene drugs

Antihistamines

Biologics

Glucocorticoids

Other

Chronic Rhinosinusitis With Nasal Polyps Segment by Application

Hospital

Clinic

Other

Chronic Rhinosinusitis With Nasal Polyps Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Rhinosinusitis With Nasal Polyps market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Rhinosinusitis With Nasal Polyps and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Rhinosinusitis With Nasal Polyps.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chronic Rhinosinusitis With Nasal Polyps market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Chronic Rhinosinusitis With Nasal Polyps manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Chronic Rhinosinusitis With Nasal Polyps in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Chronic Rhinosinusitis With Nasal Polyps in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Chronic Rhinosinusitis With Nasal Polyps Industry Trends Table 2. Chronic Rhinosinusitis With Nasal Polyps Industry Drivers Table 3. Chronic Rhinosinusitis With Nasal Polyps Industry Opportunities and Challenges Table 4. Chronic Rhinosinusitis With Nasal Polyps Industry Restraints Table 5. Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Chronic Rhinosinusitis With Nasal Polyps Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Manufacturers Table 9. Global Chronic Rhinosinusitis With Nasal Polyps Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Chronic Rhinosinusitis With Nasal Polyps Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Chronic Rhinosinusitis With Nasal Polyps Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Chronic Rhinosinusitis With Nasal Polyps Manufacturers, Product Type & Application Table 13. Global Chronic Rhinosinusitis With Nasal Polyps Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Chronic Rhinosinusitis With Nasal Polyps by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Anti-leukotriene drugs Table 17. Major Manufacturers of Antihistamines Table 18. Major Manufacturers of Biologics Table 19. Major Manufacturers of Glucocorticoids Table 20. Major Manufacturers of Other Table 21. Global Chronic Rhinosinusitis With Nasal Polyps Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Chronic Rhinosinusitis With Nasal Polyps Sales by Type (2021-2026) & (K Units) Table 23. Global Chronic Rhinosinusitis With Nasal Polyps Sales by Type (2027-2032) & (K Units) Table 24. Global Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Type (2021-2026) Table 25. Global Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Type (2027-2032) Table 26. Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Type (2021-2026) & (K Units) Table 28. Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Type (2027-2032) & (K Units) Table 29. Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Type (2021-2026) Table 30. Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Other Table 34. Global Chronic Rhinosinusitis With Nasal Polyps Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Chronic Rhinosinusitis With Nasal Polyps Sales by Application (2021-2026) & (K Units) Table 36. Global Chronic Rhinosinusitis With Nasal Polyps Sales by Application (2027-2032) & (K Units) Table 37. Global Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Application (2021-2026) Table 38. Global Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Application (2027-2032) Table 39. Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Application (2021-2026) & (K Units) Table 41. Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Application (2027-2032) & (K Units) Table 42. Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Application (2021-2026) Table 43. Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Application (2027-2032) Table 44. Global Chronic Rhinosinusitis With Nasal Polyps Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Chronic Rhinosinusitis With Nasal Polyps Sales by Region (2021-2026) & (K Units) Table 46. Global Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Region (2021-2026) Table 47. Global Chronic Rhinosinusitis With Nasal Polyps Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Chronic Rhinosinusitis With Nasal Polyps Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Chronic Rhinosinusitis With Nasal Polyps Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2021-2026) & (K Units) Table 51. North America Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2027-2032) & (K Units) Table 52. Europe Chronic Rhinosinusitis With Nasal Polyps Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2021-2026) & (K Units) Table 54. Europe Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Chronic Rhinosinusitis With Nasal Polyps Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2027-2032) & (K Units) Table 61. Global Chronic Rhinosinusitis With Nasal Polyps Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Region (2021-2026) Table 65. Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Region (2027-2032) Table 66. Teva Company Information Table 67. Teva Business Overview Table 68. Teva Chronic Rhinosinusitis With Nasal Polyps Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Teva Chronic Rhinosinusitis With Nasal Polyps Product Portfolio Table 70. Teva Recent Development Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Chronic Rhinosinusitis With Nasal Polyps Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Sanofi Chronic Rhinosinusitis With Nasal Polyps Product Portfolio Table 75. Sanofi Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Chronic Rhinosinusitis With Nasal Polyps Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Novartis Chronic Rhinosinusitis With Nasal Polyps Product Portfolio Table 80. Novartis Recent Development Table 81. GSK Company Information Table 82. GSK Business Overview Table 83. GSK Chronic Rhinosinusitis With Nasal Polyps Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. GSK Chronic Rhinosinusitis With Nasal Polyps Product Portfolio Table 85. GSK Recent Development Table 86. Wockhardt Company Information Table 87. Wockhardt Business Overview Table 88. Wockhardt Chronic Rhinosinusitis With Nasal Polyps Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Wockhardt Chronic Rhinosinusitis With Nasal Polyps Product Portfolio Table 90. Wockhardt Recent Development Table 91. West-Ward Pharmaceuticals Company Information Table 92. West-Ward Pharmaceuticals Business Overview Table 93. West-Ward Pharmaceuticals Chronic Rhinosinusitis With Nasal Polyps Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. West-Ward Pharmaceuticals Chronic Rhinosinusitis With Nasal Polyps Product Portfolio Table 95. West-Ward Pharmaceuticals Recent Development Table 96. Regeneron Company Information Table 97. Regeneron Business Overview Table 98. Regeneron Chronic Rhinosinusitis With Nasal Polyps Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Regeneron Chronic Rhinosinusitis With Nasal Polyps Product Portfolio Table 100. Regeneron Recent Development Table 101. Optinose Company Information Table 102. Optinose Business Overview Table 103. Optinose Chronic Rhinosinusitis With Nasal Polyps Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Optinose Chronic Rhinosinusitis With Nasal Polyps Product Portfolio Table 105. Optinose Recent Development Table 106. Genentech Company Information Table 107. Genentech Business Overview Table 108. Genentech Chronic Rhinosinusitis With Nasal Polyps Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Genentech Chronic Rhinosinusitis With Nasal Polyps Product Portfolio Table 110. Genentech Recent Development Table 111. AstraZeneca Company Information Table 112. AstraZeneca Business Overview Table 113. AstraZeneca Chronic Rhinosinusitis With Nasal Polyps Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. AstraZeneca Chronic Rhinosinusitis With Nasal Polyps Product Portfolio Table 115. AstraZeneca Recent Development Table 116. Apotex Corp. Company Information Table 117. Apotex Corp. Business Overview Table 118. Apotex Corp. Chronic Rhinosinusitis With Nasal Polyps Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Apotex Corp. Chronic Rhinosinusitis With Nasal Polyps Product Portfolio Table 120. Apotex Corp. Recent Development Table 121. Akorn Company Information Table 122. Akorn Business Overview Table 123. Akorn Chronic Rhinosinusitis With Nasal Polyps Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Akorn Chronic Rhinosinusitis With Nasal Polyps Product Portfolio Table 125. Akorn Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Chronic Rhinosinusitis With Nasal Polyps Distributors List Table 129. Chronic Rhinosinusitis With Nasal Polyps Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Chronic Rhinosinusitis With Nasal Polyps Product Image Figure 2. Global Chronic Rhinosinusitis With Nasal Polyps Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Rhinosinusitis With Nasal Polyps Market Size (2021-2032) & (US$ Million) Figure 4. Global Chronic Rhinosinusitis With Nasal Polyps Sales (2021-2032) & (K Units) Figure 5. Global Chronic Rhinosinusitis With Nasal Polyps Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Chronic Rhinosinusitis With Nasal Polyps Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Anti-leukotriene drugs Image Figure 9. Antihistamines Image Figure 10. Biologics Image Figure 11. Glucocorticoids Image Figure 12. Other Image Figure 13. Global Chronic Rhinosinusitis With Nasal Polyps Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Chronic Rhinosinusitis With Nasal Polyps Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Type (2021-2032) Figure 16. Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Other Image Figure 22. Global Chronic Rhinosinusitis With Nasal Polyps Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Chronic Rhinosinusitis With Nasal Polyps Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Application (2021-2032) Figure 25. Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Application (2021-2032) Figure 28. North America Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Country (2021-2032) Figure 30. U.S. Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Country (2021-2032) Figure 35. Germany Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Country (2021-2032) Figure 42. China Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Country (2021-2032) Figure 50. Brazil Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Chronic Rhinosinusitis With Nasal Polyps Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Chronic Rhinosinusitis With Nasal Polyps Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Chronic Rhinosinusitis With Nasal Polyps Revenue (2021-2032) & (US$ Million) Figure 61. North America Chronic Rhinosinusitis With Nasal Polyps Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Chronic Rhinosinusitis With Nasal Polyps Revenue (2021-2032) & (US$ Million) Figure 63. Europe Chronic Rhinosinusitis With Nasal Polyps Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Chronic Rhinosinusitis With Nasal Polyps Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Chronic Rhinosinusitis With Nasal Polyps Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Chronic Rhinosinusitis With Nasal Polyps Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Chronic Rhinosinusitis With Nasal Polyps Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-leukotriene drugs
  • Antihistamines
  • Biologics
  • Glucocorticoids
  • Other
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Teva
  • Sanofi
  • Novartis
  • GSK
  • Wockhardt
  • West-Ward Pharmaceuticals
  • Regeneron
  • Optinose
  • Genentech
  • AstraZeneca
  • Apotex Corp.
  • Akorn

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Chronic Rhinosinusitis With Nasal Polyps Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Chronic Rhinosinusitis With Nasal Polyps Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Chronic Rhinosinusitis With Nasal Polyps Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Chronic Rhinosinusitis With Nasal Polyps Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Chronic Rhinosinusitis With Nasal Polyps Market Dynamics
  1. 2.1 Chronic Rhinosinusitis With Nasal Polyps Industry Trends
  2. 2.2 Chronic Rhinosinusitis With Nasal Polyps Industry Drivers
  3. 2.3 Chronic Rhinosinusitis With Nasal Polyps Industry Opportunities and Challenges
  4. 2.4 Chronic Rhinosinusitis With Nasal Polyps Industry Restraints
3 Chronic Rhinosinusitis With Nasal Polyps Market by Manufacturers
  1. 3.1 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Manufacturers (2021-2026)
  3. 3.3 Global Chronic Rhinosinusitis With Nasal Polyps Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Chronic Rhinosinusitis With Nasal Polyps Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Chronic Rhinosinusitis With Nasal Polyps Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Chronic Rhinosinusitis With Nasal Polyps Manufacturers, Product Type & Application
  7. 3.7 Global Chronic Rhinosinusitis With Nasal Polyps Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Chronic Rhinosinusitis With Nasal Polyps Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Chronic Rhinosinusitis With Nasal Polyps Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Chronic Rhinosinusitis With Nasal Polyps Tier 1, Tier 2, and Tier 3
4 Chronic Rhinosinusitis With Nasal Polyps Market by Type
  1. 4.1 Chronic Rhinosinusitis With Nasal Polyps Type Introduction
  2. 4.1.1 Anti-leukotriene drugs
  3. 4.1.2 Antihistamines
  4. 4.1.3 Biologics
  5. 4.1.4 Glucocorticoids
  6. 4.1.5 Other
  7. 4.2 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Type
  8. 4.2.1 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Type (2021-2032)
  10. 4.2.3 Global Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Type (2021-2032)
  11. 4.3 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Type
  12. 4.3.1 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Type (2021-2032)
  14. 4.3.3 Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Type (2021-2032)
5 Chronic Rhinosinusitis With Nasal Polyps Market by Application
  1. 5.1 Chronic Rhinosinusitis With Nasal Polyps Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Application
  6. 5.2.1 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Application (2021-2032)
  8. 5.2.3 Global Chronic Rhinosinusitis With Nasal Polyps Sales Market Share by Application (2021-2032)
  9. 5.3 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Application
  10. 5.3.1 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Application (2021-2032)
  12. 5.3.3 Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Application (2021-2032)
6 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Region
  1. 6.1 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Region (2021-2032)
  3. 6.2.1 Global Chronic Rhinosinusitis With Nasal Polyps Sales by Region (2021-2026)
  4. 6.2.2 Global Chronic Rhinosinusitis With Nasal Polyps Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Chronic Rhinosinusitis With Nasal Polyps Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Chronic Rhinosinusitis With Nasal Polyps Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Chronic Rhinosinusitis With Nasal Polyps Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Region
  1. 7.1 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Region
  2. 7.1.1 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Region (2021-2026)
  4. 7.1.3 Global Chronic Rhinosinusitis With Nasal Polyps Revenue by Region (2027-2032)
  5. 7.1.4 Global Chronic Rhinosinusitis With Nasal Polyps Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Chronic Rhinosinusitis With Nasal Polyps Revenue (2021-2032)
  8. 7.2.2 North America Chronic Rhinosinusitis With Nasal Polyps Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Chronic Rhinosinusitis With Nasal Polyps Revenue (2021-2032)
  11. 7.3.2 Europe Chronic Rhinosinusitis With Nasal Polyps Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Chronic Rhinosinusitis With Nasal Polyps Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Chronic Rhinosinusitis With Nasal Polyps Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Chronic Rhinosinusitis With Nasal Polyps Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Chronic Rhinosinusitis With Nasal Polyps Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Chronic Rhinosinusitis With Nasal Polyps Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Chronic Rhinosinusitis With Nasal Polyps Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Chronic Rhinosinusitis With Nasal Polyps Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GSK Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Wockhardt
  26. 8.5.1 Wockhardt Company Information
  27. 8.5.2 Wockhardt Business Overview
  28. 8.5.3 Wockhardt Chronic Rhinosinusitis With Nasal Polyps Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Wockhardt Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
  30. 8.5.5 Wockhardt Recent Developments
  31. 8.6 West-Ward Pharmaceuticals
  32. 8.6.1 West-Ward Pharmaceuticals Company Information
  33. 8.6.2 West-Ward Pharmaceuticals Business Overview
  34. 8.6.3 West-Ward Pharmaceuticals Chronic Rhinosinusitis With Nasal Polyps Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 West-Ward Pharmaceuticals Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
  36. 8.6.5 West-Ward Pharmaceuticals Recent Developments
  37. 8.7 Regeneron
  38. 8.7.1 Regeneron Company Information
  39. 8.7.2 Regeneron Business Overview
  40. 8.7.3 Regeneron Chronic Rhinosinusitis With Nasal Polyps Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Regeneron Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
  42. 8.7.5 Regeneron Recent Developments
  43. 8.8 Optinose
  44. 8.8.1 Optinose Company Information
  45. 8.8.2 Optinose Business Overview
  46. 8.8.3 Optinose Chronic Rhinosinusitis With Nasal Polyps Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Optinose Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
  48. 8.8.5 Optinose Recent Developments
  49. 8.9 Genentech
  50. 8.9.1 Genentech Company Information
  51. 8.9.2 Genentech Business Overview
  52. 8.9.3 Genentech Chronic Rhinosinusitis With Nasal Polyps Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Genentech Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
  54. 8.9.5 Genentech Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca Chronic Rhinosinusitis With Nasal Polyps Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
  61. 8.11 Apotex Corp.
  62. 8.11.1 Apotex Corp. Company Information
  63. 8.11.2 Apotex Corp. Business Overview
  64. 8.11.3 Apotex Corp. Chronic Rhinosinusitis With Nasal Polyps Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Apotex Corp. Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
  66. 8.11.5 Apotex Corp. Recent Developments
  67. 8.12 Akorn
  68. 8.12.1 Akorn Company Information
  69. 8.12.2 Akorn Business Overview
  70. 8.12.3 Akorn Chronic Rhinosinusitis With Nasal Polyps Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Akorn Chronic Rhinosinusitis With Nasal Polyps Product Portfolio
  72. 8.12.5 Akorn Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chronic Rhinosinusitis With Nasal Polyps Value Chain Analysis
  2. 9.1.1 Chronic Rhinosinusitis With Nasal Polyps Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chronic Rhinosinusitis With Nasal Polyps Production Mode & Process
  6. 9.2 Chronic Rhinosinusitis With Nasal Polyps Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chronic Rhinosinusitis With Nasal Polyps Distributors
  9. 9.2.3 Chronic Rhinosinusitis With Nasal Polyps Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst